Theabrownin triggers DNA damage to suppress human osteosarcoma U2OS cells by activating p53 signalling pathway
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Theabrownin triggers DNA damage to suppress human osteosarcoma U2OS cells by activating p53 signalling pathway
Authors
Keywords
-
Journal
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2018-07-11
DOI
10.1111/jcmm.13742
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Physicochemical properties and cell-based bioactivity of Pu’erh tea polysaccharide conjugates
- (2017) Xiao-Qiang Chen et al. INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
- Germline and somatic genetics of osteosarcoma — connecting aetiology, biology and therapy
- (2017) D. Matthew Gianferante et al. Nature Reviews Endocrinology
- Theabrownin Inhibits Cell Cycle Progression and Tumor Growth of Lung Carcinoma through c-myc-Related Mechanism
- (2017) Li Zhou et al. Frontiers in Pharmacology
- Liver-related safety assessment of green tea extracts in humans: a systematic review of randomized controlled trials
- (2016) T Isomura et al. EUROPEAN JOURNAL OF CLINICAL NUTRITION
- Serum metabolomics analysis of rat after intragastric infusion of Pu-erh theabrownin
- (2016) Jian Liu et al. JOURNAL OF THE SCIENCE OF FOOD AND AGRICULTURE
- Green tea and liver cancer risk: A meta-analysis of prospective cohort studies in Asian populations
- (2016) Ya-Qing Huang et al. NUTRITION
- Paraptosis in the anti-cancer arsenal of natural products
- (2016) Dongjoo Lee et al. PHARMACOLOGY & THERAPEUTICS
- Targeting arachidonic acid pathway by natural products for cancer prevention and therapy
- (2016) Nagendra Sastry Yarla et al. SEMINARS IN CANCER BIOLOGY
- Chemotherapy
- (2016) Robert J. Canter Surgical Oncology Clinics of North America
- Osteosarcoma: Cells-of-Origin, Cancer Stem Cells, and Targeted Therapies
- (2016) Ander Abarrategi et al. Stem Cells International
- Anti-Proliferative and Apoptosis-Inducing Effect of Theabrownin against Non-small Cell Lung Adenocarcinoma A549 Cells
- (2016) Feifei Wu et al. Frontiers in Pharmacology
- Bone microenvironment signals in osteosarcoma development
- (2015) Arantzazu Alfranca et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Tea consumption and the incidence of cancer
- (2015) Yu-Fei Zhang et al. EUROPEAN JOURNAL OF CANCER PREVENTION
- CD133+CD44+Cells Mediate in the Lung Metastasis of Osteosarcoma
- (2015) Aina He et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Osteosarcoma: Current Treatment and a Collaborative Pathway to Success
- (2015) Michael S. Isakoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting the DNA Damage Response in Cancer
- (2015) Mark J. O’Connor MOLECULAR CELL
- Green tea polyphenol EGCG suppresses osteosarcoma cell growth through upregulating miR-1
- (2015) Kewei Zhu et al. TUMOR BIOLOGY
- MicroRNAs and Potential Targets in Osteosarcoma: Review
- (2015) Valerie B. Sampson et al. Frontiers in Pediatrics
- Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2014) ANNALS OF ONCOLOGY
- EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment†
- (2014) J. S. Whelan et al. ANNALS OF ONCOLOGY
- Recent advances in osteosarcoma
- (2014) Sander M Botter et al. CURRENT OPINION IN PHARMACOLOGY
- Green tea (Camellia sinensis) extract inhibits both the metastasis and osteolytic components of mammary cancer 4T1 lesions in mice
- (2014) Ke-Wang Luo et al. JOURNAL OF NUTRITIONAL BIOCHEMISTRY
- Pharmacologic activation of wild-type p53 by nutlin therapy in childhood cancer
- (2013) Tom Van Maerken et al. CANCER LETTERS
- Tumoricidal effects of a selenium (Se)-polysaccharide from Ziyang green tea on human osteosarcoma U-2 OS cells
- (2013) Yucai Wang et al. CARBOHYDRATE POLYMERS
- Green tea polyphenol epigallocatechin-3-gallate (EGCG) as adjuvant in cancer therapy
- (2013) Elena Lecumberri et al. CLINICAL NUTRITION
- Zebrafish xenografts as a tool for in vivo studies on human cancer
- (2012) Martina Konantz et al. Annals of the New York Academy of Sciences
- Epigallocatechin-3-gallate (EGCG) for Clinical Trials: More Pitfalls than Promises?
- (2011) Derliz Mereles et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Addition of pamidronate to chemotherapy for the treatment of osteosarcoma
- (2010) Paul A. Meyers et al. CANCER
- Emerging drugs for high-grade osteosarcoma
- (2010) Claudia Maria Hattinger et al. EXPERT OPINION ON EMERGING DRUGS
- Effects of Theabrownin from Pu-erh Tea on the Metabolism of Serum Lipids in Rats: Mechanism of Action
- (2010) Jiashun Gong et al. JOURNAL OF FOOD SCIENCE
- Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects
- (2010) Katherine A Janeway et al. LANCET ONCOLOGY
- High-throughput in vivo vertebrate screening
- (2010) Carlos Pardo-Martin et al. NATURE METHODS
- The zebrafish:scalable in vivo modeling for systems biology
- (2010) Rahul C. Deo et al. Wiley Interdisciplinary Reviews-Systems Biology and Medicine
- Targeting the osteosarcoma cancer stem cell
- (2010) Valerie A Siclari et al. Journal of Orthopaedic Surgery and Research
- Phytochemicals in Cancer Prevention and Therapy: Truth or Dare?
- (2010) Maria Russo et al. Toxins
- Osteosarcoma incidence and survival rates from 1973 to 2004
- (2009) Lisa Mirabello et al. CANCER
- Long-term results of the Spanish Protocol SO-95 for the treatment of non-metastatic high-grade osteosarcoma of the extremities in children
- (2009) Arturo Muñoz et al. Clinical & Translational Oncology
- Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss ofCdkn2
- (2009) Alexander B Mohseny et al. JOURNAL OF PATHOLOGY
- A Novel ATM-Dependent Pathway Regulates Protein Phosphatase 1 in Response to DNA Damage
- (2008) X. Tang et al. MOLECULAR AND CELLULAR BIOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search